Program
volrustomig
Also written as “Volrustomig”, “MEDI5752” and “AZD9592 + Volrustomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Carcinoma, Renal Cell, led by 2 companies.
Drug pageVolrustomig: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 1716 open or running | phase 3since Aug 2, 2023 | Mar 28, 2018 | Jan 29, 2027phase 1 · NCT07000149 |
| Presage Biosciences | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
volrustomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel, Daiichi Sankyo and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Presage Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 1, 2020First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04541108 · 15 enrolled · United States
- Jul 21, 2022Named volrustomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, MEDI5752
- Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06366451 · 17 enrolled · United States
Ahead
- Dec 2031Primary completion: early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04541108
TargetBeta
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CT…”NCIt, read by Claude
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 2 Presage Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06366451Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Completed | Mar 25, 2026 | 17 |
| NCT04541108Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Active, not recruiting | Dec 2031 | 15 |
How it is read
Names in the registry
- “Volrustomig”, 14 entries
- “MEDI5752”, 4 entries
- “AZD9592 + Volrustomig”, 2 entries
- “volrustomig”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Renal Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.